title: [Impact of octreotide on pancreatic fistula after pancreaticoduodenectomy: a prospective study].
abstract: OBJECTIVE
  To investigate the effect of utilizing octreotide during perioperative period on pancreatic fistula after pancreaticoduodenectomy (PD).
  
  
  METHODS
  Three hundreds and six patients admitted from January 2010 to October 2014, who prepared to undergo pancreaticoduodenectomy (PD) were randomly divided into octreotide group (147 cases) and control group (159 cases). In octreotide group, octreotide was used in subcutaneous injection instantly after PD, each 8 hours until postoperative 10(th) day, and patients in control group were injected with the same volume of saline. Differences of pancreatic fistula (Grade A, Grade B, Grade C), hospitalization days and treatment cost were compared. χ(2) test, t-test and Fisher exact test were used to analyzed to the data, respectively.
  
  
  RESULTS
  No statistical significance (P>0.05) between two groups in the incidence of pancreatic fistula after PD (Grade A: 8.8% vs. 10.2%, Grade B: 2.7% vs. 4.4%, Grade C: 0.7% vs. 1.3%; χ(2)=0.197, 0.700, 0.288; P=0.657, 0.403, 0.591), the length of hospitalization((12.1±1.2)days vs. (13.0±1.2)days)(t=1.711, P=0.104) and treatment cost (79 700±6 700 vs. 77 600±5 200)(t=1.378, P=0.185). When accompanied with high risk factors, such as soft texture of pancreas, pancreatic duct size less than 3 mm, BMI≥25 kg/m(2) and diabetes, compared with control group, octreotide group had the lower incidence rate of pancreatic fistula and clinical correlative pancreatic fistula(all P<0.05) after PD.
  
  
  CONCLUSIONS
  Generally, octreotide makes no contribution to reduce the incidence of pancreatic fistula after PD. However, for patients who is accompanied with high risk factors, such as soft texture of pancreas, pancreatic duct size less than 3 mm, BMI≥25 kg/m(2) and diabetes, octreotide can effectively prevent pancreatic fistula after PD.
authors.affiliation: Department of Pancreatic and Biliary Surgery, the First Affiliated Hospital, Harbin Medical University, Harbin 150001, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Kong
authors.forename: Jisheng
authors.initials: J
authors.lastname: Hu
authors.forename: Le
authors.initials: L
authors.lastname: Li
authors.forename: Gang
authors.initials: G
authors.lastname: Wang
authors.forename: Hua
authors.initials: H
authors.lastname: Chen
authors.forename: Xuewei
authors.initials: X
authors.lastname: Bai
authors.forename: Yongwei
authors.initials: Y
authors.lastname: Wang
authors.forename: Linfeng
authors.initials: L
authors.lastname: Wu
authors.forename: Hongchi
authors.initials: H
authors.lastname: Jiang
authors.forename: Bei
authors.initials: B
authors.lastname: Sun
mesh_terms: D000714:Anastomosis, Surgical; D006801:Humans; D015994:Incidence; D015282:Octreotide / Q000627:therapeutic use*; D010179:Pancreas / Q000473:pathology; D010180:Pancreatectomy; D010183:Pancreatic Ducts / Q000473:pathology; D010185:Pancreatic Fistula / Q000188:drug therapy*; D016577:Pancreaticoduodenectomy / Q000009:adverse effects*; D059035:Perioperative Period; D011446:Prospective Studies
chemical_list: D015282:Octreotide